294 related articles for article (PubMed ID: 27465973)
1. Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.
Seinen ML; van Nieuw Amerongen GP; de Boer NK; Mulder CJ; van Bezu J; van Bodegraven AA
Ther Drug Monit; 2016 Oct; 38(5):621-7. PubMed ID: 27465973
[TBL] [Abstract][Full Text] [Related]
2. A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients.
Deben DS; Creemers RH; van Adrichem AJ; Drent R; Merry AHH; Leers MPG; van Bodegraven AA; Wong DR
Sci Rep; 2022 Sep; 12(1):15806. PubMed ID: 36138194
[TBL] [Abstract][Full Text] [Related]
3. Rac1/pSTAT3 expression: A pharmacodynamic marker panel as a first step toward optimization of thiopurine therapy in inflammatory bowel disease patients.
Deben DS; van Adrichem AJ; Drent R; Puts S; Pelzer KEJM; van Bodegraven AA; Wong DR; Leers MPG
Cytometry A; 2022 Feb; 101(2):167-176. PubMed ID: 34595833
[TBL] [Abstract][Full Text] [Related]
4. Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease.
Lev-Tzion R; Renbaum P; Beeri R; Ledder O; Mevorach R; Karban A; Koifman E; Efrati E; Muise AM; Chowers Y; Turner D
J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):404-7. PubMed ID: 25885881
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
6. Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux JB; Peyrin-Biroulet L; Sparrow MP
Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
[TBL] [Abstract][Full Text] [Related]
7. Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases.
Atreya I; Diall A; Dvorsky R; Atreya R; Henninger C; Grün M; Hofmann U; Schaeffeler E; López-Posadas R; Daehn I; Zenker S; Döbrönti M; Neufert C; Billmeier U; Zundler S; Fritz G; Schwab M; Neurath MF
J Crohns Colitis; 2016 Oct; 10(10):1132-43. PubMed ID: 27112707
[TBL] [Abstract][Full Text] [Related]
8. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
[TBL] [Abstract][Full Text] [Related]
9. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
[TBL] [Abstract][Full Text] [Related]
10. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
Amin J; Huang B; Yoon J; Shih DQ
Inflamm Bowel Dis; 2015 Feb; 21(2):445-52. PubMed ID: 25248004
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
Jharap B; Seinen ML; de Boer NK; van Ginkel JR; Linskens RK; Kneppelhout JC; Mulder CJ; van Bodegraven AA
Inflamm Bowel Dis; 2010 Sep; 16(9):1541-9. PubMed ID: 20155846
[TBL] [Abstract][Full Text] [Related]
12. Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?
Heerasing NM; Ng JF; Dowling D
Intern Med J; 2016 Apr; 46(4):465-9. PubMed ID: 26425841
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
[TBL] [Abstract][Full Text] [Related]
15. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.
Dotan I; Werner L; Vigodman S; Agarwal S; Pfeffer J; Horowitz N; Malter L; Abreu M; Ullman T; Guzner-Gur H; Halpern Z; Mayer L
Inflamm Bowel Dis; 2012 Feb; 18(2):261-8. PubMed ID: 21438101
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease.
Lord JD; Shows DM
World J Gastroenterol; 2017 May; 23(18):3240-3251. PubMed ID: 28566883
[TBL] [Abstract][Full Text] [Related]
17. Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease.
Meijer B; Seinen ML; Leijte NN; Mulder CJ; van Bodegraven AA; de Boer NK
Ther Drug Monit; 2016 Aug; 38(4):463-70. PubMed ID: 27158876
[TBL] [Abstract][Full Text] [Related]
18. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
20. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
